The structure-specific ERCC1/XPF endonuclease complex that contains the ERCC1 and XPF subunits is implicated in the repair of two distinct types of lesions in DNA: nucleotide excision repair (NER) for ultraviolet-induced lesions and bulky chemical adducts; and recombination repair of the very genotoxic interstrand cross-links.
Background
The nucleotide excision repair (NER) process recognizes and eliminates a very broad spectrum of structurally diverse DNA lesions [1] . The consequences of inborn defects in NER are apparent from the rare human autosomal recessive syndrome xeroderma pigmentosum (XP), characterized by ultraviolet light (UV) sensitivity to the sun, pigmentation abnormalities, strong predisposition to skin cancer in exposed areas, and frequently accelerated neurodegeneration. Two other distinct NER disorders have been recognized in humans: the severe neurodevelopmental conditions Cockayne syndrome (CS) and trichothiodystrophy (TTD) (for a review see [2] and references therein). In remarkable contrast to XP, neither CS nor TTD is apparently associated with a clear predisposition to skin cancer. These three NER syndromes are genetically heterogeneous and comprise at least ten complementation groups: seven in XP (XP-A to XP-G), two in CS (CS-A and CS-B) and three in TTD (TTD-A, and two that are simultaneously XP groups: XP-B and XP-D) [3] .
In addition to the human NER disorders, there is a second type of mammalian NER mutant: UV-sensitive rodent cell lines (complementation groups 1-11, which can be corrected by human ERCC genes). The ERCC1 gene corrects the repair defects of group 1 mutants, which are (like other NER mutants) sensitive to UV, but which alone with group 4 mutants are additionally very sensitive to DNA cross-linking agents [4] . ERCC1 is not implicated in any of the known XP, CS or TTD complementation groups [5] .
The NER process entails damage recognition followed by a 'cut-and-paste' mechanism involving a large number of proteins [3, 6] . The ERCC1 product was recently found to reside with the XPF protein (also known as ERCC4) in a complex which constitutes a structure-specific endonuclease responsible for the incision in the damaged strand 5′ of the lesion [7, 8] . The first 214 amino acids of the ERCC1 protein are significantly homologous to the yeast NER factor RAD10 [9] , which is complexed with RAD1, the yeast homologue of XPF [10, 11] . Importantly, both yeast homologues are involved in two processes: NER and a mitotic recombination pathway [12] . This explains the sensitivity of ERCC1 and ERCC4 mutants to DNA crosslinks, which require mitotic recombination for their repair. The remaining carboxy-terminal 80 amino acids of ERCC1, which are not similar to RAD10, share clear homology with the carboxyl terminus of the Escherichia coli NER endonuclease UvrC [13] , and are also similar to numerous other nucleases [14] . Consistent with an anticipated nuclease-related function of this domain, our previous mutational analysis of ERCC1 has revealed that deletion of the last four amino acids mildly affects NER and cross-link repair, but that truncation of five or six residues severely impairs both repair functions [14] . In contrast, deletion of the less conserved first 91 residues has no significant effect on its function.
A severe ERCC1 mouse mutant, which displayed disturbed growth, reduced life span and abnormalities of liver nuclei, was described previously by McWhir and collaborators [15] . In our study, we have generated two types of mouse mutated at ERCC1: one in which the gene is 'knocked out' and one in which it is partially inactivated by introducing, into the encoded protein, a carboxy-terminal truncation that starts immediately after the carboxy-terminal UvrChomologous region. We have previously shown that this seven amino-acid truncation includes two amino acids of the domain found to be important for ERCC1 function as determined in vitro, but does not cause dramatic protein instability [14] . In addition to the features of ERCC1-mutant mice described by McWhir and coworkers [15] , we provide evidence for spleen, kidney and cutaneous deficits, and also a detailed analysis of NER, cross-link repair, cell cycle arrest and replicative senescence. Importantly, our results suggest that the accumulation of endogenous crosslinks as a result of ERCC1 inactivation leads to genomic instability and significantly contributes to ageing in mice.
Results

Targeting of the ERCC1 gene in embryonic stem cells
The minimal size of the functional ERCC1 protein that we have previously deduced from in vitro deletion analysis [14] is depicted schematically in Figure 1a . The targeting constructs used for knockout and partial inactivation of the gene and the various probes used for screening and verification of the homologous recombination are outlined in Figures 1b and 2b . The knockout vector consisted of an approximately 9.5 kb isogenic mouse genomic HindIII/SalI DNA fragment, in which a pMC1-neo cassette [16] interrupts exon 7, thus aborting the essential carboxy-terminal 74 amino acids (Fig. 1b) .
The design of a construct for a more subtle mutation, truncating the protein close to the end of the essential region, was complicated. The human and mouse ERCC1 loci contain another gene of unknown function which overlaps the last exon of ERCC1 in the antisense direction ( [17] and data not shown). In order to avoid interference with this function, we inserted the neo marker into the last intron of ERCC1. This strategy gave the additional advantage that ERCC1 transcription and mRNA processing would remain intact and that the neo resistance gene would be removed by splicing. The replacement-type vector also introduced a premature stop codon at position 292 of mouse ERCC1, removing the last seven amino acids (note that the mouse ERCC1 protein has one residue more than human ERCC1). Thus, the encoded protein (ERCC1 *292 ) terminates immediately after the UvrC-homologous region (Figs 1a,2a) . Our previously reported ERCC1 mutational analysis indicated, however, that the truncation removes just two amino acids of the ERCC1 essential domain, but should not dramatically decrease protein stability [14] .
Targeting of both constructs was evaluated by Southern blot analysis using unique probes that hybridize outside the targeting constructs (Figs 1c,2c ). The frequency of homologous recombination for the knockout and ERCC1 *292 constructs was approximately 5% (8 of 170 G418-resistant transformants) and 13% (23 of the 172 clones analyzed), respectively. In the case of the ERCC1 *292 mutation, two of the independent embryonic stem (ES) cell clones were also analyzed by reverse-transcriptase-coupled polymerase chain reaction (RT-PCR), using ERCC1-specific cDNA primers and DNA sequencing to verify the presence of the mutation and to ensure that the rest of the coding region, which was part of the targeting construct, was still intact after the process of homologous recombination.
Generation of ERCC1-mutant mice and analysis of ERCC1 expression
F2 offspring from each of two independent ERCC1 knockout and ERCC1 *292 ES cell clones were born, and expression of the targeted gene was analyzed at the mRNA level in mouse embryonic fibroblasts (MEFs), using RT-PCR and dot-blot analysis (Fig. 3 ). Filters were hybridized with wild-type or mutant-specific 32 P-labelled oligonucleotides, which distinguished ERCC1 *292 transcripts from wild-type. PCR products from fibroblasts of F2 offspring of the ERCC1-knockout ES cell clones hybridized only to the wild-type-specific primer if the offspring were wild-type homozygous or heterozygous, whereas no mRNA could be detected in homozygous mutant MEFs. RNA from heterozygous ERCC1 *292 MEFs clearly hybridized to both probes; in homozygous mutant ERCC1 *292 MEFs, only mutant transcript could be detected. We conclude that the knockout allele is transcriptionally inactivated and that the ERCC1 *292 allele is still transcribed and, as shown by sequence analysis (data not shown), is properly processed.
In order to determine the relative levels of ERCC1 *292 message more accurately, RT-PCR products (from ERCC1 *292 ES cells) were subcloned. Dot-blot analysis revealed that, in 9 out of 70 recombinant clones, the desired mutation could be detected (data not shown), indicating that the transcript level from the ERCC1 *292 allele is reduced to about 15% of the level of the non-targeted allele. In an attempt to confirm the observation that there was detectable ERCC1 transcript in the ERCC1 *292 mice, we tested tissue extracts from ERCC1 *292 mice and their wild-type litter-mates using ERCC1-specific antibodies; however, all the available antibodies, which were raised against the human ERCC1 protein, did not recognize the mouse protein. To test for expression of the antisense gene at the ERCC1 locus, northern blot analysis of kidney and liver RNA was performed; a probe corresponding to the mouse genomic ERCC1 3′ region (probe C; see Fig. 1b ) that hybridizes to the antisense mRNA revealed a transcript of 5-6 kb that was expressed in tissues of wildtype, ERCC1 *292 and ERCC1 knockout mice (data not shown), indicating that gene targeting did not alter the expression level of the antisense transcript.
Phenotype, frequency of recovery, and pathology of ERCC1-mutant mice
In order to investigate the effects of genetic background on embryonic lethality and life span, in addition to the C57Bl/6/129 hybrid ERCC1 knockout and ERCC1 *292 mice, whose generation we have described, we also generated FVB/129 hybrid ERCC1 *292 mice. A number of the characteristics of ERCC1 deficiency have been described by McWhir et al. [15] , and are confirmed in both our (Fig. 4) and a markedly reduced life span. Life span reduction was more severe in our ERCC1 knockout mice (C57Bl/6 background) and the FVB-background ERCC1 *292 mice, which had maximal ages of 38 days and 78 days, respectively; C57Bl/6-background ERCC1 *292 mice had a life span of up to 6 months. The ERCC1-mutant mice reported by McWhir et al. [15] died between days 20 and 28. We also noted sex differences in phenotype for the C57Bl/6-background ERCC1 *292 mice: male mice were more severely runted (only 25% of the weights of controls, compared with 30-50% for females) and had a shorter life span (data not shown).
We investigated when lethality (embryonic or post partum) occurred and whether these features were influenced by genetic background. Both ERCC1 knockout and ERCC1 *292 mice in a C57Bl/6/129 background revealed early embryonal lethality (by day 13.5 after gestation; pathological abnormalities in the heart, lung, brain and eyes, nor any of the characteristics often found in XP patients, such as neurological abnormalities, premalignant lesions or immature sexual development (in mice up to 6 months old). By morphological criteria, the ovaries and testes, although proportionately small, looked normal: ovaries contained ova and follicles, sometimes with signs of cyclic changes, indicating normal pituitary regulatory function, and spermatogenesis also appeared normal. ERCC1 *292 mice that reached the age of approximately 6 months, however, gave no progeny when mated with C57Bl/6 mice, suggesting that they were infertile. Figure 5 shows the histopathology of ERCC1 *292 mice; identical results were obtained with ERCC1 knockout mice (data not shown).
Previously, McWhir et al. [15] reported light-microscopically detectable abnormalities in liver nuclei of ERCC1-mutant mice. We observed similar nuclear abnormalities ( Fig. 5d ), but in addition, the kidney, skin and spleen were found to be abnormal. The skin of ERCC1 *292 mice was thin and lacked subcutaneous fat (Fig. 5a,b ). In the spleen of mutant mice at 3 weeks of age, an increased and early onset of ferritin deposition was found ( Fig. 5c ), which was absent from age-matched wild-type mice (data not shown). The peripheral blood in some samples showed an increase in Howel Jolly bodies (data not shown). The increase in ferritin deposition might point to an increased turnover of erythrocytes; however, there was no sign of overt haemochromatosis. In the kidney, we found dilated tubules containing leaked proteinaceous material ( Fig. 5e ), indicative of renal dysfunction, as well as nuclear abnormalities; these kidney abnormalities were not seen in wild-type litter-mates (data not shown).
Electron microscopy confirmed and extended the mutantspecific nuclear abnormalities in liver and kidney (seen in Fig. 5d ,f and also McWhir et al. [15] ): the chromatin was very coarse, and the nucleoli were more prominent than normal and showed an abnormal organization (Fig. 5g) . Furthermore, nuclear invagination and intranuclear inclusions were observed (Fig. 5h ). Flow cytometry of liver cells of young ERCC1 *292 mice showed increasing octaploidy (Fig. 6a) . The abnormal nuclear morphology was also reflected in the distribution of nuclear size, as revealed by nominal area measurements in liver sections (Fig. 6b ).
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Figure 3
RT-PCR and dot-blot analysis of ERCC1 transcripts. Exons 9 and 10 of the mouse ERCC1 locus were amplified by RT-PCR (using total MEF RNA from embryos on embryonic day 13.5 ). Amplified DNA from homozygous wild-type (+/+), heterozygous (+/-) and homozygous mutant (-/-) offspring of both ERCC1 *292 (*292) and ERCC1 knockout (ko) F1 heterozygotes was dot-blotted and hybridized to labelled oligonucleotide probes specific for (a) ERCC1 *292 (p81) and (b) wild-type ERCC1 (p228). (c) As a control, amplimers specific for mouse XPB were added to the cDNA mix and amplified DNA was hybridized to an XPB-specific oligonucleotide probe (p73). As a control for the specificity of hybridization of the mutant and wild-type ERCC1-specific oligonucleotides, both wild-type (wt-tc) and ERCC1 *292 (*292-tc) targeting constructs were also spotted. The ERCC1 *292 mutation causes reduced growth. Homozygous wildtype (back) and homozygous mutant (front) 3-4 week old litter-mates (C57Bl/6/129 hybrid background) from a heterozygous ERCC1 *292 intercross. Table 1 Genotype of offspring and embryos derived from mice heterozygous for mutations in ERCC1. Both embryos (from embryonic day E13.5) and neonates (10 days post partum) were genotyped by Southern blot analysis using probe A (see Fig. 1b) ; the numbers and proportions of homozygous wild-type (+/+), heterozygous (+/-) and homozygous mutant (-/-) mice are shown. *C57Bl/6/129 hybrid background. † FVB/129 hybrid background. ‡ All -/-mice and embryos of both genotypes displayed severe growth retardation.
In order to find out whether excess programmed cell death was involved in the growth deficit associated with ERCC1 mutation, serial-sectioned liver, kidney and spleen tissue were analyzed using the TUNEL assay [18] . No clear increase in TUNEL-positive nuclei was seen in the organs from ERCC1-mutant mice compared to those from wildtype litter-mates (data not shown). These results indicate that excessive apoptosis did not occur in ERCC1-mutant mice and suggest that the reduced size of these mice was due to either a reduction or an early halt to proliferation.
Growth and cell cycle properties of ERCC1-mutant fibroblasts
Because the reduced size of ERCC1-mutant mice suggested a potential role for ERCC1 in cell proliferation, we measured growth rates of primary ERCC1 *292 MEFs in vitro. Early-passage (passage 3) ERCC1-mutant MEFs grew about three times as slowly as wild-type fibroblasts; heterozygous MEFs had a doubling time of 36 hours compared with 24 hours for wild-type fibroblasts (Fig. 7a) . Proliferation decreased with passage in culture and, by passage 6-7, fibroblasts from ERCC1 *292 mice failed to divide, whereas MEFs from heterozygous and wild-type litter-mates grew quite rapidly (three independent cell lines of each genotype were tested). The homozygous mutant MEFs were larger than wild-type cells and contained giant polyploid nuclei (compare Fig. 7a In order to analyze cell cycle properties, we pulse-labelled cells with BrdU for 1 hour, and followed their progression through the cell cycle. In the cycling population (which was close to 50% for ERCC1 *292 fibroblasts), the relative distribution of cells in the different cell cycle phases was similar for ERCC1 increase of chromosomal breaks, gaps and abberations compared with wild-type controls (data not shown).
DNA repair parameters of ERCC1-mutant fibroblasts
McWhir et al. [15] reported increased UV sensitivity and reduced incision and dimer removal after UV exposure for cells derived from their ERCC1-deficient mouse mutant. In order to extend these findings, we analyzed DNA repair and incision using an assay for UV-induced unscheduled DNA synthesis (UDS) of primary MEFs (three independent cell lines from each genotype). UDS in ERCC1 *292 cells was extremely low (4% of that of wild-type cells; Fig.   8 ). Interestingly, fibroblasts from heterozygous litter-mates showed a slight, but significant, reduction in UDS (to a level of 73% that of wild-type controls). Similar results were obtained with ERCC1 knockout cells (data not shown).
As an estimate of another repair parameter, we measured cell survival after exposure to various genotoxic agents. In addition to the UV sensitivity (Fig. 9a) we investigated sensitivity to DNA cross-linking agents. A hallmark of chinese hamster ovary cell lines that contain mutations in ERCC1 (or ERCC4) is their extreme sensitivity (80-100-fold above controls) to cross-linking agents, presumably
Research reflecting the role of the ERCC1 complex in recombinational repair. As shown in Figure 9b , most ERCC1-mutant MEFs displayed a clear sensitivity to MMC, but a small fraction seemed resistant to MMC concentrations over a wide range. Comparable survival curves were obtained when another cross-linking agent, cisplatin, was used (data not shown), ruling out the possibility of a defect in drug metabolism. Moreover, when we examined the survival of the ERCC1-mutant MEFs after treatment with 7,12-dimethylbenz[a]anthracene (DMBA), a chemical agent that causes only bulky adducts, which are substrates for NER, a profound sensitivity was found (Fig. 9c) that was in the same range as that for XPA -/-cells [19] . No resistant cell population was apparent, however, indicating that the resistance is specific to the removal of cross-linking lesions, which are largely eliminated by recombinational repair.
A possible explanation for the ERCC1-mutant cell population resistant to DNA cross-linking is the existence of another recombination repair process (for example, homology-dependent recombination repair) active only at a specific stage of the cell cycle and requiring cell cycle arrest. As shown in Figure 7c , the mechanism of damage-induced G2 cell cycle arrest is still functional in the ERCC1-mutant MEFs. Unfortunately, the limited lifespan of the primary MEFs precluded retesting of the resistant cell fraction for MMC sensitivity. A similar bimodal behaviour was found, however, for some chinese hamster ovary NER mutants: in this case, the resistant fraction showed the same survival as the original cell population (data not shown), consistent with the explanations given above. Transfection of immortalized mouse ERCC1 *292 fibroblasts with wild-type human ERCC1 cDNA fully complemented the UV sensitivity (Fig. 9d) , indicating that the repair defect is the result of ERCC1 targeting. From this set of experiments, we conclude that both the ERCC1 knockout and ERCC1 *292 mice have a severe NER defect and a deficiency in cross-link repair.
Carcinogenicity studies
In order to establish whether the ERCC1 *292 mice are susceptible to developing skin cancer, four three-week-old mutant mice were exposed to 30 g DMBA, followed by a promotion protocol (2.5 g TPA administration twice a week). As a control, both heterozygous and wild-type litter-mates (20 of each) were divided into four groups, each receiving 0, 5, 15 or 30 g DMBA, followed by the TPA treatment. The dose given to ERCC1-mutant mice was chosen because XPA -/-mice, which are also totally NER-deficient, treated with the same dose showed only reversible skin abnormalities (Fig. 10d) . However, treated ERCC1-mutant mice displayed massive epidermal necrosis and minimal infiltration of leucocytes (Fig. 10c) . All ERCC1-mutant mice died three days after the first administration of DMBA, whereas XPA -/-mice appeared normal (both strains are in the same 129/C57Bl/6 hybrid genetic background). These data indicate that ERCC1-mutant mice are much more sensitive to DMBA than are XPA -/-mice, which is in contrast to the corresponding MEFs, which are equally DMBA-sensitive (Fig. 9c) 
Discussion
Comparison of the ERCC1 knockout and ERCC1 *292 alleles at the molecular and phenotypical level
Besides its involvement in NER, the ERCC1-XPF endonuclease is also implicated in the repair of crosslinks, most likely via a mitotic recombination repair pathway. Consequently, a defect in this gene is expected to cause a combination of features derived from deficiencies in both systems. Our previous mutational analysis of ERCC1 has shown that many of the alterations to the middle part of the protein render it unstable, presumably by impairment of the stabilizing interaction with XPF [14] . On the other hand, deletion of five or six carboxyterminal amino acids affects both ERCC1 repair functions but does not dramatically destabilize the protein [14] . In addition, we found that a low level of ERCC1-XPF may be sufficient for the repair of very genotoxic DNA crosslinks, but not for NER [14] . In view of the dual function of the protein and the notion that its total inactivation results in a very severe phenotype [15] , we decided to generate two types of ERCC1-mutant mouse model: an ERCC1 knockout mouse, and one in which the ERCC1 protein contained a seven amino acid carboxy-terminal truncation (equivalent to deleting six residues of the human protein). In RT-PCR experiments using ERCC1 knockout MEFs, no ERCC1 mRNA could be detected. This excludes the possibility of dominant-negative effects of a truncated ERCC1 protein and indicates that the knockouts represent true null mutants. In contrast, RNA expression was detected for the ERCC1 *292 allele, but the level of transcript was only about 15% of the expected level, probably as a consequence of the marker insertion
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Figure 10
Acute effects in the skin of ERCC1 *292 and XPA -/-mice after treatment with DMBA. Shaved mice (3 weeks of age) were treated with a single dose of 30 g DMBA. Three days after treatment, part of either the exposed skin or untreated skin from dead ERCC1 *292 -mutant mice or sacrificed control animals was sampled and processed for histopathology; skin is shown at 270× magnification. and/or the mutation. MEFs heterozygous for ERCC1 *292 revealed a small but significant reduction (27%) in UVinduced UDS (Fig. 8) . Independently, McWhir et al. [15] reported a similar decrease in the level of incision and an accumulation of DNA breaks in MEFs heterozygous for a mutation in ERCC1. These findings point to haplo-insufficiency -the normal NER capacity is diminished when there is only one functional ERCC1 allele. This suggests that, under normal conditions, ERCC1 is a rate-limiting factor in NER of MEFs.
Both at the cellular level and at the level of the organism, the ERCC1 knockout and ERCC1 *292 phenotypes are very alike and each mutation has a dramatic effect on NER. In view of the anticipated partial stability of the ERCC1 *292 protein, and the fact that it still harboured the intact UvrChomologous domain, the ERCC1 *292 mice might have displayed a partial defect in cross-link repair. This was not found, however. Therefore, protein truncation as well as reduced transcript levels may have made the ERCC1 *292 phenotype more severe than anticipated. The major phenotypic difference between the ERCC1 knockout and ERCC1 *292 -mutant mice, however, seemed to be in the life span. The ERCC1 knockout mice all died before day 38, whereas the maximum life span of ERCC1 *292 mutants was considerably longer (6 months). All the ERCC1-mutant mice described by McWhir and coworkers [15] died even earlier than our knockout mutants, between days 20 and 28. Furthermore, we showed that both genetic background and sex influenced the penetrance of embryonal and perinatal lethality and of lifespan alterations.
Comparison with other NER-deficient mouse models and genotype-phenotype correlations
The consequences for the mouse of a defect solely in NER are apparent from the XPA knockout mouse. XPA -/-mice are viable, develop normally and have a normal life span, but are photosensitive and predisposed to UVinduced skin cancer and ocular tumours [19, 20] . XPA -/-MEFs have a total NER deficiency and are hypersensitive to UV and DMBA [19, 20] . The effects of NER loss -confirmed by the phenotype of the XPC knockout mice, which have a specific defect in the global genome repair subpathway of NER [21, 22] -are mild compared with the effects of ERCC1 *292 . McWhir et al. [15] proposed accumulation of an endogenously generated NER lesion as the cause of the ERCC1-mutant features. As the NER defect in XPA null and ERCC1 null mutants is the same, however, this explanation has become unlikely. Instead, we infer that in the ERCC1 *292 mice, the extra pathological characteristics, which lack a parallel in the human XP patients, must be due to the additional ERCC1 function. Thus, the liver, kidney and spleen manifestations, as well as the developmental delay and reduced life span, are most probably derived from impairment of the interstrand cross-link repair pathway. The same holds true at the cellular level for the striking features of the ERCC1-mutant MEFs; namely the nuclear abnormalities (including enlarged polyploid nuclei and nuclear inclusions) and, importantly, replicative senescence.
How can we explain the 'non NER' clinical manifestations in terms of inactivation of ERCC1-dependent crosslink repair? The liver and kidney malfunctions are probably the consequence of the prominent nuclear abnormalities seen in these organs. Polyploid nuclei normally develop later in life, but are already apparent at, or soon after, birth in ERCC1-mutant mice. Other indications also point to premature senescence, such as the occurrence of eosinophilic nuclear inclusions, which have frequently been observed in cells of ageing animals [23] . In addition, the striking early onset of a proliferative arrest of ERCC1 *292 MEFs (with a concomitant increase in p21 cip1/waf1 ), which is due to the presence of a large proportion of cells arrested in the cell cycle, is a hallmark of replicative senescence (see [24] for a recent overview). The early stop in cellular proliferation may also explain the severe reduction in weight, the poor and delayed development, and early death. Thus, ERCC1-mutant mice display several signs of premature senescence. What is the relationship between premature senescence and impaired cross-link repair? The involvement of defective cross-link repair suggests that accumulation of interstrand cross-links causes the observed phenomena. Candidates for endogenous agents inducing such lesions are mutagenic carbonyl compounds such as malondialdehyde (MDA), which is the major by-product of arachidonic acid metabolism and lipid peroxidation [25] . MDA produces adducts (mainly at deoxyguanosine) and induces interstrand cross-links, which have been detected in liver DNA, for example, and have been implicated in carcinogenesis [25] .
Persistent DNA damage triggers p53 accumulation, which in turn induces cell cycle arrest, thereby providing a timewindow for DNA repair and the prevention of mutagenesis [26] . Moreover, p53 has been implicated in a spindle checkpoint that controls the ploidy of cells [27] . One of the most important downstream effectors induced by p53 is the cell cycle inhibitor p21 cip1/waf1 [28] , which has also been associated with cell differentiation and senescence. The involvement of p21 cip1/waf1 in the ERCC1-dependent cross-link repair pathway is strongly supported by the striking resemblance of ERCC1 *292 mice to transgenic mice that express high levels of p21 cip1/waf1 in the liver [29] . These mice display dramatically inhibited hepatocyte proliferation, resulting in aberrant tissue organization, runted liver and body growth and increased mortality; furthermore, large polyploid nuclei were observed, also suggesting arrest during the G2 phase of the cell cycle [29] .
The body of evidence for the involvement of p21 cip1/waf1 and p53 in ERCC1-dependent cross-link repair is compelling: first, as mentioned before, we find higher levels of p21 cip1/waf1 in untreated ERCC1 *292 MEFs than in wild-type controls; second, McWhir and coworkers [15] have shown accumulation of p53 in liver, kidney and brain of ERCC1-mutant mice; and third, under certain conditions, p53 activation triggers apoptosis in response to DNA damage [30] , although overexpression of p21 cip1/waf1 in liver cells does not lead to increased apoptosis [29] . Similarly, we failed to detect high levels of apoptosis in either ERCC1-mutant mice or cultured ERCC1-mutant MEFs (data not shown). In summary, our data, supported by many independent findings, suggest that very genotoxic lesions, such as MDA-induced DNA cross-links, which are normally targeted by the ERCC1-dependent recombination pathway, accumulate at a high rate in ERCC1-mutant mice, and activate p53. In turn, p53 induces p21 cip1/waf1 , resulting in early cell cycle arrest, nuclear polyploidy and other cellular abnormalities. These features of premature senescence cause liver and kidney malfunction, arrested development and early death. Thus, endogenously generated cross-links may be an important factor in the process of ageing, and ERCC1-dependent recombination may constitute a critical barrier against senescence.
ERCC1 and human repair syndromes
ERCC1 is one of the few NER genes for which no corresponding human (repair) disorder is known. This may be due to the severe consequences of ERCC1 inactivation, which cause prenatal or early postnatal death. As in the case of the XPF subunit of the ERCC1/XPF endonuclease, a mutation affecting only the NER function, but leaving sufficient amounts of complex for its role in crosslink repair, is expected to give a phenotype very similar to that of XP-F patients [7, 14] . The XP-F complementation group is characterized by relatively mild XP features, with late onset of symptoms. Fibroblasts from XP-F patients still perform a low level (15-20%) of DNA repair [31] . Apparently, the low concentration of the ERCC1-XPF complex in these cells is rate-limiting for NER but still permits some repair to occur. This concentration may be sufficient to cope with a low steady-state DNA-damage load. Moreover, for high UV doses, a low but long-lasting type of repair activity has been observed in XP-F cells [32] . In the end, this may still permit removal of a considerable fraction of the lesions.
The phenotype of the ERCC1-mutant mice described here may provide clues for a corresponding syndrome in man resulting from a more severe impairment of ERCC1 function. In extrapolating to man, it should be kept in mind that, except for the repair parameters, the genetic background in mice already appears to have a significant effect on the penetrance and expressivity of the clinical features. With this caveat in mind, rare genetically heterogeneous, autosomal recessive disorders such as Roberts syndrome may be considered potential candidates for an ERCC1 defect. Roberts syndrome patients display a variety of developmental anomalies, including renal defects and malignancies. Interestingly, some patients exhibit, at the cellular level, nuclear (heterochromatin) abnormalities and UV sensitivity as well as cross-link sensitivity [33] . In one Roberts syndrome patient, we failed to find defects in ERCC1 at either the DNA or RNA level (data not shown); however, this does not exclude ERCC1 mutations in other cases. Very recently, we have identified an XP patient with a mutation assigned to the XPF component of the dual functional ERCC1/XPF endonuclease who has a number of unusual features including growth defects and premature senescence, indicating the existence of further parallels between the mouse ERCC1-mutant system and human syndromes (our unpublished observations). A more versatile experimental animal model for ERCC1 deficiencies, which might direct assignment of the clinical parameters to the different ERCC1 activities, awaits the generation of mouse mutants with specific defects in each of the ERCC1 functions.
Materials and methods
Targeting constructs and disruption of ERCC1 in ES cells
Genomic ERCC1 fragments were obtained by screening a 129/CCE EMBL4 genomic library (kindly provided by G. Grosveld) with a murine ERCC1 cDNA [19] . A knockout targeting construct was prepared by subcloning a ~9.5 kb HindIII/SalI fragment containing murine ERCC1 exons 6-10 into pBR322. A unique ClaI restriction site was generated in exon 7 by uracil-DNA-mediated mutagenesis as described before [34] , using primer p89 (5′ TCCAGCTTATCGATAAGGAGGT). The pMC1-neo resistance gene [16] , containing a diagnostic BamHI restriction site, was inserted into the unique ClaI site, yielding pE1NEO7. The ERCC1 *292 targeting construct was generated as follows. A 2.8 kb KpnI/XbaI fragment containing ERCC1 murine exons 7-10 was subcloned into pTZ19 (Pharmacia). Using sitedirected mutagenesis as described above, a stop codon was introduced into mouse ERCC1 exon 10, deleting the amino-terminal 7 amino acids, using primer p81 (5′ GGCACTTTGAGGGATCC-TATTCGTGTAGTACT). In addition, we introduced a unique ClaI restriction site in intron 9, approximately 350 bp upstream of exon 10, in order to insert the pMC1-neo resistance gene, using primer p82 (5′ TAGTACATCGATGGGCGG). All critical regions were confirmed by double-stranded-DNA sequence analysis [35] .
The targeting constructs were separated from vector sequences by gel electrophoresis, purified by electroelution and introduced into 129/Oladerived ES cells by electroporation (E14 cells were kindly provided by A. Berns and H. te Riele). Routinely, 1 × 10 7 cells were electroporated in ES medium, supplemented with fetal calf serum (FCS) and containing 10-15 g linearized targeting vector, at 585 V cm -1 , 1200 F, for 10 msec using a Progenetor II PG200 gene pulser (Hoeffer). Cells were seeded onto gelatin-coated 10 cm dishes (10 6 cells per plate) and, after 24 h, subjected to neomycin selection (200 g ml -1 ) in Dulbeccos' modified Eagles medium (DMEM) containing 60% Buffalo rat liver conditioned medium (BRL) [36] and supplemented with 10% FCS, 1% non-essential amino acids, 0.1 mM 2-mercaptoethanol and LIF (1000 units ml -1 ; Gibco). After 6-7 days, individual G418-resistant clones were picked into 24-well dishes (Costar) and expanded (no feeder layer). Half of the cells in the 24-well dish was expanded and frozen at -80°C, and the other half was used to identify targeted events. Chromosomal DNA was extracted from expanded cultures as described previously [37] , digested with BamHI, and analyzed by Southern blot analysis using probe A (a genomic 5′~0.3 kb HindIII fragment containing intron sequences flanking the targeting construct. Targeted clones were reconfirmed using probe C (an internal 3′~1.2 kb XbaI/KpnI fragment 3′ of the ERCC1 gene) and probe B (a probe covering the neo coding region) (see Fig. 1 ). All homologous recombinants showed bands diagnostic for correct integration of the neo marker without random integration of additional copies of the targeting construct. In case of the ERCC1 *292 mutation, two independent ES clones were analyzed by RT-PCR. Mouse ERCC1 cDNA harbouring the ERCC1 *292 mutation was subjected to RT-PCR using primers p141 (5′ TTGTTC-AAGTGGATG) and p92 (5′ CTGGGCATGGAAAATTC) to amplify the region covering the mouse ERCC1 gene that was part of the targeting construct. The PCR fragment was subcloned into an M13mp18-cloning vector and individual clones were analyzed by replica-plating using mutant-specific p81 primer and wild-type-specific p228 primer (5′ GGCACTTTGAGGAAGGGTTCGTGTAGTACT). Two ES cell lines from each targeting experiment were used for blastocyst injection.
The complete 1.1 kb human ERCC1 cDNA fragment was inserted into the pBluescript vector KS + (Stratagene). A ~2.4 kb human elongation factor-1␣ (EF1␣) promoter fragment [38] , including the first intron, was inserted into the 5′-end of this construct. The 2.4 kb poly(A) fragment of the human ␤-globin was inserted in the 3′-end of this construct, yielding peF1␣E1. The plasmid pCMVE1 is similar to peF1␣E1, but contains the CMV promoter instead of the EF1␣ promoter.
Generation of ERCC1-mutant mice and culturing of MEFs
Chimeric mice were obtained by injecting 10-15 ES cells of the two different types of ERCC1-mutant clones into C57Bl/6 blastocysts. ES cells were karyotyped before injection. An average of 8 blastocysts was transferred into pseudopregnant female recipient BCBA mice. Male chimeras were bred to C57Bl/6 animals to generate the ERCC1-mutant mice described in this study. In addition, male chimeras were also bred to FVB animals to investigate the effects of genetic background on embryonic lethality and lifespan. Targeted ES cell clones produced male chimeras whose germline transmitted the agouti coat colour marker in nearly all offspring. Homozygous ERCC1-mutant mice were obtained by intercrossing F1 heterozygotes. Southern blot analysis of tail DNA (using probe A; Fig. 1a ) was used to genotype the offspring, using standard conditions.
MEFs were isolated from day 12-13 embryos. Part of the embryo was used for genotyping. The remaining embryonic tissue was minced using a pair of scissors and immersed in a thin layer of F10/DMEM culture medium supplemented with 10% FCS and antibiotics. After 24 h, 5 ml culture medium was added and after 4-5 days, the culture was trypsinized and cultured up to passage 6-9. Spontaneous immortalized cell lines were obtained by continuous subculturing of primary MEFs. DNA transfections of immortalized MEFs were performed using lipofectin (Gibco).
UDS, survival assays and in vivo DMBA treatment
For UDS testing, fibroblasts (passage 4-6) were seeded onto coverslips at day zero. The next day, cells were washed with phosphatebuffered saline (PBS) and irradiated with 16 J m -2 UV-C (Philips, TUV lamp). Subsequently, cells were incubated for 2.5 h in culture medium containing 10 Ci ml -1 [ 3 H]thymidine (50 Ci mmol -1 ; Amersham), fixed and subjected to autoradiography as described before [39] .
For survival assays, primary MEF cultures were exposed to UV or incubated with MMC for 1 h and allowed to grow for another 4-5 days before reaching confluency. Cells were labelled with [ 3 H]thymidine as described above, rinsed thoroughly with PBS and lysed in 0.2 M NaOH. The number of proliferating cells in each dish was estimated by scintillation counting of the radioactivity incorporated during a 3 h pulse-labelling. Cell survival was expressed as the ratio of irradiated over unirradiated cells. For DMBA treatment, cells were incubated with DMBA-containing medium for 2 h on day one. To activate DMBA, a microsomal S9-fraction (TNO-voeding, Zeist) was added. Cells were washed twice and grown until day six. Cell survival was measured by addition of the tetrazolium salt XTT (final concentration 0.12 mg ml -1 ) to the culture medium. The amount of formazan dye formed after 2 h incubation was measured using an enzyme-linked immunosorbent assay reader, as described by the manufacturer (Boehringer).
For the in vivo DMBA experiment, about four weeks after birth, 20 ERCC1 +/+ and 20 ERCC1 +/-mice were treated once a week on the shaved back with 0, 5, 15 and 30 g DMBA dissolved in 100 l acetone; ERCC1 -/-mice (4) received only the 30 g DMBA treatment.
After DMBA treatment, the mice received the phorbol ester TPA (2.5 g in 100 l acetone) twice a week for twenty weeks.
Histological studies and electron microscopical analysis
Before postmortem examination, all animals were sacrificed by cervical dislocation. Tissues were fixed in 10% neutral buffered formalin. Following appropriate fixation times, tissues were trimmed, dehydrated through ascending grades of ethyl alcohol, cleared in xylene, and infiltrated with paraffin wax. Tissue sections of 4 m were prepared and stained with haematoxylin and eosin. Ferritin staining was performed as described by Simpson et al. [40] . Sections (4 m) were cut and stained with haematoxylin and eosin and Perls's for iron. For electron microscopy, liver and kidney were fixed in a mixture of glutaraldehyde (1.5%) and paraformaldehyde (1.5%) in phosphate buffer at pH 7.3. Organs were postfixed in 1% OsO 4 , 1.5% potassium hexanoferrate, rinsed in cacodylate and 0.2 M sodium maleate buffers (pH 6.0), and block-stained with 1% uranyl acetate. Following dehydration, tissues were embedded in Epon.
Flow cytometry and morphometric measurements
Replicative DNA synthesis and DNA content were analyzed using bivariate flow cytometry according to established protocols [41] . Liver cells were stained with propidium iodine and analyzed on a FACScan cytometer using the Lysis II program (Becton-Dickinson). For cell cycle analysis, exponentially growing passage-3 MEFs were labelled with 10 M BrdU (Boehringer) at 37°C for 1 h and then mock-treated or incubated with MMC (0.4 g ml -1 for 1 h). After the chase period, cells were fixed with 75% ethanol. Fixed cells were treated with 0.1 M HCl containing 0.5% Triton X-100, followed by heating at 95°C and rapid cooling to denature DNA. Cells were then incubated with florescein isothiocyanate-conjugated anti-BrdU antibodies (Boehringer) and counter stained with 2 g ml -1 propidium iodine. For morphometric measurement of the nuclear diameters, 3 m-thick sections were stained according to Mayer. Automated image analysis was carried out using a Zeiss large research microscope fitted with a Bosch monochromatic camera connected to a Kontron IBAS 2000 image analysis system (Kontron Bildanalyse). A 6.3× objective was used, giving a measurement field on liver section of 2.8 mm 2 , which was enlarged 100× on the instrument monitor to give 306 pixels mm -1 of original image.
Reverse transcription PCR and dot-blot analysis
Total RNA was isolated from tissues by the LiCl/urea method [42] . The RNA was used for preparing cDNA with ERCC1-specific primers. Amplification was performed by 30 cycles of, consecutively, 2 min denaturing at 95°C, 2 min annealing at around 50°C and 3 min extension at 70°C. Amplified DNA was spotted onto nitrocellulose filters and hybridized to wild-type and mutant 32 P-labelled primers. Mutation detection was performed by RT-PCR on RNA isolated from day E13.5 MEFs. A 3′ mouse ERCC1 cDNA fragment was amplified by PCR with oligonucleotides p1 (5′ CCTTATGCCCGGGCCTGGGCCCAC) and p2 (5′ TTATTGTGACATGGGCTAGGTGGC). Amplified DNA was spotted on nitrocellulose filters and hybridized with labelled oligonucleotide probes p81 (specific for the ERCC1 *292 mutation) and p228 (wild-type-specific; 5′ GGCACTTTGAGGAAGGGTTCGTGTAGTACT).
To assure that the samples were equally capable of undergoing amplification of specific sequences by the PCR method, amplimers specific for the mouse XPB gene -p108 (5′ CGACGCTGTGGCACCAT-GAG) and p73 (5′ AACCTAGGACCCACGAAGG) -were added to the cDNA mix and hybridized to a mouse XPB specific primer, p30 (5′ GCTGCCTGGATCCGTG).
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